Prevymis (letermovir) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 2 Diseases   32 Trials   32 Trials   1662 News 


«12...13141516171819202122232425»
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Review, Journal:  Letermovir for cytomegalovirus prophylaxis. (Pubmed Central) -  Aug 2, 2019   
    Vaccines and cell therapies for CMV must be further developed. No abstract available
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Clinical, Journal:  Letermovir associated hepatic transaminitis: A case report. (Pubmed Central) -  Jul 11, 2019   
    This report highlights a case of letermovir associated transaminitis with successful rechallenge through peak and recovery of the hepatic serum enzymes. Because there is currently no published evidence to support the adverse event, the temporal relationship and response to rechallenge that was observed is essential to establishing the probable causality in this case.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), maribavir (TAK-620) / Takeda, GSK
    Journal:  Cytomegalovirus infections (Pubmed Central) -  Jul 11, 2019   
    As screening for congenital infection by serology is not recommended so far, it will be realized in an evocative context. Therapeutic options are still limited and expose to haematological or renal toxicity, but new antivirals (maribavir, letermovir) should be available soon to optimize therapeutic management.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Clinical, Retrospective data, Journal:  Letermovir as Salvage Therapy for CMV Infection in Transplant Recipients. (Pubmed Central) -  May 21, 2019   
    Its favourable efficacy and safety profile re-opens door for antiviral prophylaxis another first-line option, similar to CMV surveillance-preemptive therapy, for preventing CMV in allogeneic HSCT recipients. We demonstrate mixed efficacy in patients with refractory CMV infection suggesting that letermovir may be a useful therapeutic adjunct, potentially in combination with other antivirals.
  • ||||||||||  Vistide (cidofovir) / Gilead
    Review, Journal:  New Developments in the Management of Cytomegalovirus Infection After Transplantation. (Pubmed Central) -  May 17, 2019   
    In this review, we highlight the role of the newly approved drug, letermovir, a viral terminase inhibitor, for CMV prevention after allogeneic hematopoietic stem cell transplantation...The role of adoptive immunotherapy, using ex vivo-generated CMV-specific T cells, is highlighted. This article provides a review of novel drugs, tests, and strategies in optimizing our current approaches to prevention and treatment of CMV in transplant recipients.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Clinical, Journal:  Letermovir for prophylaxis of cytomegalovirus manifestations in adult allogeneic hematopoietic stem cell transplant recipients. (Pubmed Central) -  May 14, 2019   
    This molecule could become a paradigm-shifting drug in preventing CMV manifestations based on its novel mechanism of action, lack of cross-resistance with available drugs, proven efficacy in a large randomized clinical trial, and its beneficial toxicity and tolerability profile. Drug-drug interactions and the lack of any activity against other viruses are the main shortcomings of letermovir.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Clinical, Journal:  Pharmacological and clinical effects of letermovir (Prevymis), a novel anti-human cytomegalovirus prophylactic drug (Pubmed Central) -  May 5, 2019   
    HCMV infection and disease in recipients of allogeneic hematopoietic stem cell transplant (HSCT) is a serious disease leading to significant morbidity and mortality. In the Phase 3 trial, the preventive effect of clinically significant HCMV infection by oral or intravenous administration of letermovir in allogeneic HSCT patients was confirmed, and letermovir was well tolerated with no suggestions of myelotoxicity or nephrotoxicity.
  • ||||||||||  Vistide (cidofovir) / Gilead
    Journal:  Anticytomegalovirus Peptides Point to New Insights for CMV Entry Mechanisms and the Limitations of In Vitro Screenings. (Pubmed Central) -  Apr 9, 2019   
    Recently, letermovir, a terminase complex inhibitor, was approved for prophylaxis after stem cell transplantation...While these antiviral peptides are highly effective at inhibiting cell-free virus, they do not inhibit MCMV cell-to-cell spread. This underscores the need to understand the mechanism of cell-to-cell spread and differences between in vivo-derived versus in vitro-derived CMV entry to effectively prevent CMV's spread.
  • ||||||||||  Review, Journal:  Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation. (Pubmed Central) -  Apr 7, 2019   
    Fourteen trials that compared antiviral prophylaxis with placebo demonstrated overall effectiveness in reducing incidence of CMV infection (odds ratio [OR], 0.49; 95% confidence interval [CI], 0.42-0.58), CMV disease (OR, 0.56; 95% CI, 0.40-0.80), and use of preemptive therapy (OR, 0.51; 95% CI, 0.42-0.62; 6 trials); however, none demonstrated reduction in all-cause mortality (OR, 0.96; 95% CI, 0.78-1.18) except the phase 3 trial of letermovir (week-24 OR, 0.59; 95% CI, 0.38-0.98). Additional research is warranted to determine patient groups most likely to benefit from antiviral prophylaxis and its optimal deployment after allogeneic HCT.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), acyclovir / Generic mfg.
    Clinical impact of CMV replication in overall survival in allogeneic haematopoietic cell transplant patients () -  Apr 5, 2019 - Abstract #ECCMID2019ECCMID_1301;    
    Those patients that received preemptive therapy had a significant inferior overall survival compared with those that replicate CMV but didn’t receive preemptive therapy. This reinforce the relevance of prophylactic strategies for CMV with drugs with good safety profile like letermovir that in a randomised trial proved to decrease the need for preemptive therapy.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Cytovene (ganciclovir) / Roche
    Journal:  A fifty-year odyssey: Prospects for a cytomegalovirus vaccine in transplant and congenital infection. (Pubmed Central) -  Feb 17, 2019   
    The review will also describe newer developments that have upended the efforts towards such a vaccine through the discovery of a second pathway of CMV infection that utilizes an alternative receptor for entry using a series of antigens that have been determined to be important for prevention of infection. Expert Commentary: There is a concerted effort to unify separate therapeutic and prophylactic vaccine strategies into a single delivery agent that would be effective for both transplant-related and congenital infection.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Enrollment open:  Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection (clinicaltrials.gov) -  Jan 14, 2019   
    P2,  N=32, Recruiting, 
    Expert Commentary: There is a concerted effort to unify separate therapeutic and prophylactic vaccine strategies into a single delivery agent that would be effective for both transplant-related and congenital infection. Not yet recruiting --> Recruiting